Clinical studies have also shown that the levels of ADA2 in biological fluids are increased in other pathophysiological conditions, such as HIV infection and breast cancer (12–14) and dramatically decreased in patients with ADA2 deficiency (DADA2) (15). This evidence concerns the gene ADA2 and deficiency of adenosine deaminase 2.